secwatch / observer
8-K filed June 11, 2026, 4:44 PM ET ticker KALV CIK 0001348911
M&A confidence high sentiment neutral materiality 1.00

KalVista Pharmaceuticals, Inc. (KALV): M&A transaction — Chiesi completes $27/share acquisition of KalVista; shares cease trading on Nasdaq

KalVista Pharmaceuticals, Inc.

item 1.01item 1.02item 2.01item 3.01item 5.01item 2.03item 3.03item 5.03item 5.02item 7.01item 9.01
Featured in Daily 8-K Digest
Selected #5 for 2026-06-11. Read digest

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Fairey

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Departed

Patrick Treanor

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Departed

Brian J. G. Pereira, MD

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Appointed

John Hess

Sole Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Filed
June 11, 2026, 4:44 PM ET
John Hess, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company
Departed

Bethany Sensenig

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Departed

Edward W. Unkart

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Departed

Laurence Reid, PhD

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Departed

Benjamin L. Palleiko

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Departed

Nancy Stuart

Director
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Successor
John Hess
Filed
June 11, 2026, 4:44 PM ET
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
Appointed

John Hess

Other Named Officer
KALV · KalVista Pharmaceuticals, Inc.
Effective
2026-06-11
Filed
June 11, 2026, 4:44 PM ET
John Hess, President and Secretary of Purchaser, became an officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Fairey resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick Treanor resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brian J. G. Pereira, MD resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John Hess was appointed as Sole Director at KalVista Pharmaceuticals, Inc..

Action
became the sole director
Role
Sole Director
Exact text from the filing
John Hess, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Bethany Sensenig resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Edward W. Unkart resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Laurence Reid, PhD resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Benjamin L. Palleiko resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy Stuart resigned as Director at KalVista Pharmaceuticals, Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John Hess was appointed as other_named_officer at KalVista Pharmaceuticals, Inc..

Action
became an officer
Exact text from the filing
John Hess, President and Secretary of Purchaser, became an officer of the Company.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

KalVista Pharmaceuticals, Inc.: Amended and restated bylaws in full.

Change
bylaw amendment
Exact text from the filing
as of the Effective Time, the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in full
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

KalVista Pharmaceuticals, Inc.: Amended and restated certificate of incorporation in its entirety.

Change
charter amendment
Exact text from the filing
As of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

KalVista Pharmaceuticals, Inc. underwent a change of control involving Chiesi Farmaceutici S.p.A. for $27.00 per Share in cash (closed 2026-06-11).

Action
change of control
Counterparty
Chiesi Farmaceutici S.p.A.
Consideration
$27.00 per Share in cash
Closing
2026-06-11
Exact text from the filing
Purchaser commenced a tender offer (the “ Offer ”) to acquire all of the outstanding shares of common stock of the Company, par value $0.001 per share (the “ Shares ”), for $27.00 per Share, net to the seller in cash, without interest and subject to any withholding of taxes (the “ Offer Price ”). The Offer and withdrawal rights expired at one minute
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

KalVista Pharmaceuticals, Inc. terminated Company 2015 Incentive Plan with KalVista Pharmaceuticals, Inc. valued at Terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company (effective 2026-06-11).

Action
termination
Counterparty
KalVista Pharmaceuticals, Inc.
Value
Terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company
Effective
2026-06-11
Exact text from the filing
In connection with the consummation of the Offer and the Merger and effective as of, and contingent upon, the Effective Time, the Company terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company 2021 Equity Inducement Plan.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

KalVista Pharmaceuticals, Inc. terminated Company 2017 Employee Stock Purchase Plan with KalVista Pharmaceuticals, Inc. valued at Terminated the Company 2017 Employee Stock Purchase Plan (effective 2026-06-11).

Action
termination
Agreement
equity purchase
Counterparty
KalVista Pharmaceuticals, Inc.
Value
Terminated the Company 2017 Employee Stock Purchase Plan
Effective
2026-06-11
Exact text from the filing
In addition, and also effective immediately prior to, and contingent upon, the Effective Time, the Company terminated the Company 2017 Employee Stock Purchase Plan.
View on SEC.gov

241 governance changes filed in the last 30 days. Browse all governance changes →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001140361-26-024949
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.